Nucleoside in Medical Technology
Navigation Links
Nucleoside in Medical Technology
... more potent than Pharmasset's first generation nucleoside polymerase inhibitor, RG7128 (formerly known as ... toxicities that may be associated with some nucleoside analogs. Like RG7128, PSI-7851 has demonstrated ... clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase ...
... of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency ... of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV ... protease inhibitor, with InterMune, and R7128, a nucleoside polymerase inhibitor, with Pharmasset. ...
... has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development ... support the efficacy and safety of R7128, and nucleoside polymerase inhibitors as a class," said Michelle ... Pharmasset's Chief Medical Officer. "We believe nucleoside inhibitors have a number of advantages over other ...
... this week in Milan, Italy. Second-Generation nucleoside Polymerase Inhibitor Program IDX184 is a ... potency than the first-generation HCV nucleoside clinical drug candidates currently in ... "The preclinical profiles emerging in our HCV nucleoside and protease inhibitor programs are very ...
... R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is ... that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care ... is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug ...
... liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic ...
... for rheumatoid arthritis as well." Thiarabine is a next generation nucleoside analogue that Access has licensed from Southern Research. It has been in ... and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in ...
... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also show ... to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors, and non-nucleosides that, through virtue of binding at a ...
... 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor. ANA598 Phase I Study Results In the Phase I ... with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies ...
... This approach represents a potential opportunity to preserve nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), ... N Engl J Med 2007; 356: 1723-35. (10) The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in ...
... to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. In addition, ... interferon-alpha, a representative protease inhibitor and a representative nucleoside polymerase inhibitor. About ANA598 Preclinical evaluation of ANA598 ...
... hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...
... approximately 15- to 20-fold greater than the in vitro potency of R7128, a nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing through ... or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is ...
... hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...
... proprietary SEPA polymer technology, for the treatment of onychomycosis, a condition commonly known as nail fungus. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...
... oral nucleotide prodrug candidate based on Idenix's proprietary liver-targeting technology. This technology enables the delivery of high levels of nucleoside triphosphate in the liver, potentially maximizing drug efficacy and limiting systemic side effects. In HCV genotype-1 infected chimpanzees, ...
... currently not on treatment." About R7128 R7128, being developed for the treatment of chronic HCV infection, is a pro-drug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically modified form of a molecule designed to enhance the absorption, distribution and ...
... virologic response (SVR) after being off of therapy for 24 weeks, the primary endpoint of the study. Clevudine is an oral, once-daily pyrimidine nucleoside analog that has been evaluated in 18 clinical trials in more than 800 individuals. Phase 3 studies are currently being conducted in approximately 140 ...
... development pipeline in all three therapeutic areas of focus, including: -- Announced positive preliminary results for RDEA806, our lead non- nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a monotherapy study in patients with human-immunodeficiency virus (HIV), demonstrating ...
... number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be used in combination with multiple other anti-HCV agents, ...
... of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency ... of an oral protease inhibitor and an oral nucleoside polymerase inhibitor resulted in significant HCV ... protease inhibitor, with InterMune, and R7128, a nucleoside polymerase inhibitor, with Pharmasset. ...
... has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development ... support the efficacy and safety of R7128, and nucleoside polymerase inhibitors as a class," said Michelle ... Pharmasset's Chief Medical Officer. "We believe nucleoside inhibitors have a number of advantages over other ...
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
... About PSI-7851 PSI-7851 is a uridine nucleoside analog currently in developed for the treatment ... metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies ... toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in ...Pharmasset Receives Notice of Allowance
... No. 10/828,753 titled, "Modified Fluorinated nucleoside Analogues," covering the composition of matter of ... property rights in our growing pipeline of HCV nucleoside polymerase inhibitors," stated Schaefer Price, ... is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug ...... this week in Milan, Italy. Second-Generation nucleoside Polymerase Inhibitor Program IDX184 is a ... potency than the first-generation HCV nucleoside clinical drug candidates currently in ... "The preclinical profiles emerging in our HCV nucleoside and protease inhibitor programs are very ...
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
... Risk of Toxicity Associated with nucleoside Class of HIV Drugs KENILWORTH, N.J., April 15 ... Truvada is a combination product in the nucleoside reverse transcriptase inhibitor (NRTI) class. ... 356: 1723-35. 9 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of ...... R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is ... that there appear to be certain synergies between nucleoside polymerase inhibitors and the standard of care ... is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug ...
Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
... in San Francisco, CA. Second-Generation nucleoside Polymerase Inhibitor Program Idenix's preclinical HCV nucleoside polymerase inhibitor program comprises two novel ... technology, which delivers high levels of nucleoside triphosphate in the liver, potentially ...Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
... of our knowledge, this is the first example of a nucleoside analog triphosphate showing non-competitive inhibition. Potent Antiviral Activity of the nucleoside HCV Inhibitor, R7128, in Prior IFN ... early evidence of high genetic barrier for nucleoside inhibitors of NS5B polymerase. The safety and ...R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
... R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being ... antiviral drug combinations, and nucleoside polymerase inhibitors such as R7128 could improve ... potent antiviral activity of any investigational nucleoside HCV polymerase inhibitor to date in ...... liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic ...
... for rheumatoid arthritis as well." Thiarabine is a next generation nucleoside analogue that Access has licensed from Southern Research. It has been in ... and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in ...
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
... download from the journal's website. "Thiarabine is a next generation nucleoside analogue, licensed by Access from Southern Research Institute ," stated ... factor and is targeted to breast cancer. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in ...... of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also show ... to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors, and non-nucleosides that, through virtue of binding at a ...
Pharmasset Reports Fiscal Year End 2008 Financial Results
... progress with our hepatitis C virus (HCV) programs. R7128, our lead HCV nucleoside inhibitor, completed 28 day clinical studies in both treatment naive and ... treatment. These efforts provide the groundwork for our next generation of nucleoside and nucleotide inhibitors, such as PSI-7851, that hold the potential for ...... 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor. ANA598 Phase I Study Results In the Phase I ... with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies ...
... This approach represents a potential opportunity to preserve nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), ... N Engl J Med 2007; 356: 1723-35. (10) The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in ...
... to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. In addition, ... interferon-alpha, a representative protease inhibitor and a representative nucleoside polymerase inhibitor. About ANA598 Preclinical evaluation of ANA598 ...
... hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...
... approximately 15- to 20-fold greater than the in vitro potency of R7128, a nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing through ... or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is ...
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
... 2 or 3 patients, this would demonstrate a distinct clinical attribute of nucleoside polymerase inhibitors." Please see http://www.clinicaltrials.gov or ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...... hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through ... of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified ...
Pharmasset Reports First Fiscal Quarter 2008 Financial Results
... for the treatment of HCV. -- Discovered a new series of proprietary nucleoside analogs that have demonstrated potent anti-HCV activity. ... activities. -- Conducting preclinical studies of a proprietary anti-HCV nucleoside analog to support first-in-human clinical trials, once a lead ...Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
... in Glasgow, Scotland. R7128 is a prodrug of PSI- 6130, an oral cytidine nucleoside analog polymerase inhibitor of hepatitis C virus (HCV) that is being ... demonstrated potency in preclinical studies. PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for ...Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
... a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine , a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35. 7 The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. ...Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
... of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration ...TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
... said TriLink CEO, Dr. Richard Hogrefe. About TriLink TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR ...TriLink Launches CleanAmp(TM) dNTPs for Hot Start PCR
... compared to the modified enzymes available on the market." About TriLink TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, nucleoside triphosphates and CleanAmp(TM) Products for research and diagnostic laboratories. In addition, custom chemistry, contract research services and GMP ...Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
... to infection with e-antigen positive hepatitis B virus (QUASH 305) or e-antigen positive (QUASH 306) who have never been treated with drugs of the nucleoside class. The primary objective of the studies are to assess the effect of clevudine on reducing levels of virus in the blood and normalization of liver ...... proprietary SEPA polymer technology, for the treatment of onychomycosis, a condition commonly known as nail fungus. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, ...
... oral nucleotide prodrug candidate based on Idenix's proprietary liver-targeting technology. This technology enables the delivery of high levels of nucleoside triphosphate in the liver, potentially maximizing drug efficacy and limiting systemic side effects. In HCV genotype-1 infected chimpanzees, ...
... currently not on treatment." About R7128 R7128, being developed for the treatment of chronic HCV infection, is a pro-drug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A pro-drug is a chemically modified form of a molecule designed to enhance the absorption, distribution and ...
Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
... minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, and smoking). About Abacavir Abacavir sulfate is a nucleoside reverse transcriptase inhibitor with a proven safety and efficacy profile as part of an HIV treatment regimen. Abacavir is a key component in ...Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
... in both in vitro and in vivo preclinical models. Pre-clinical testing suggests that this technology enables the delivery of high levels of active nucleoside triphosphate into the liver, the site of primary HCV infection. In HCV genotype-1 infected chimpanzees, once-daily oral administration of 10 mg/kg of ...... virologic response (SVR) after being off of therapy for 24 weeks, the primary endpoint of the study. Clevudine is an oral, once-daily pyrimidine nucleoside analog that has been evaluated in 18 clinical trials in more than 800 individuals. Phase 3 studies are currently being conducted in approximately 140 ...
... development pipeline in all three therapeutic areas of focus, including: -- Announced positive preliminary results for RDEA806, our lead non- nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a monotherapy study in patients with human-immunodeficiency virus (HIV), demonstrating ...
... number of replicon mutations known to confer resistance to other anti-HCV agents currently in clinical development, including protease inhibitors and nucleoside polymerase inhibitors. This data confirms the broad potential utility of ANA598 to be used in combination with multiple other anti-HCV agents, ...
ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
... Alberta on March 30, 2008. The preclinical results demonstrate a unique resistance profile for ANX-201 and suggest suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs to treat HIV. The HIV Pathogenesis Conference is part of the Keystone ...Other ContentstachycardiatachycardiaventricularventricularventricularventricularventricularinsufficiencyinsufficiencyinsufficiencyinsufficiencyinsufficiencyviolenceviolenceviolenceviolenceverrucaconjunctivitisconjunctivitisarthritisarthritisarthritisarthritisarthritisarthritisarthritisOther Tagsnetworknetworknetworknetworkdesigneddesigneddesignedrewardrewardyetyetyetinksinksinkswhale
(Date:12/16/2009)... 9 BIO-key International, Inc. (OTC ... biometric identification solutions, today announced that SC ... security publications, named BIO-key International the 2009 ... Control sub-category Biometrics. ,, (Logo: ... technology editor, SC Magazine, "Biometric providers have ...
(Date:12/15/2009)... 15 The 2009 Frost & ... is presented to Sagem Securite (Safran Group) ... The award recognises the company,s expertise in ... in offering novel, value-added products to end ... ) ,, "Sagem Securite has been involved ...
(Date:12/15/2009)... the British Society for Research on Ageing (BSRA) to ... for an initial period of three years. ... Biogerontology editorial board and will acquire articles for ... society and provide society members with free electronic access ... Biogerontology offers a platform for research which ...
Breaking Biology News(10 mins):BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Auroras Milwaukee Hospitals Recognized in US News and World Report 51970 1Auroras Milwaukee Hospitals Recognized in US News and World Report 51970 2VIVIMIND 28TM 29 granted certificate of free sale as food supplement in Italy Premarket notification filed in the U S 51966 1VIVIMIND 28TM 29 granted certificate of free sale as food supplement in Italy Premarket notification filed in the U S 51966 2VIVIMIND 28TM 29 granted certificate of free sale as food supplement in Italy Premarket notification filed in the U S 51966 3Omnicell to Release Second Quarter 2009 Earnings Results on July 23 51961 1Omnicell to Release Second Quarter 2009 Earnings Results on July 23 51961 2(Date:12/17/2009)... Physicians Healthcare Management Group, Inc. (Phyhealth) ... it has issued its financial statements for the ... are being posted today on the Pink Sheets ... Management Group, Inc. ,, Physicians Healthcare ... community-based health maintenance organizations (HMOs) that are owned ...
(Date:12/17/2009)... characteristics involved in the exposure of pregnant women to ... standing up or have to lift heavy objects, 63% ... are frequently exposed to some physical risk in their ... especially sensitive to exposure to workplace hazards", M Carmen ... at the Higher Centre for Public Health Research in ...
(Date:12/17/2009)... Stem cells that could one day provide therapeutic ... harvested from the tissue of the umbilical cord, just ... cells to treat some blood disorders, said University of ... version of the Journal of Biomedicine and ... be expanded to greater number, are remarkably stable and ...
(Date:12/17/2009)... Science in Human Resource Development Degree Online , ... ... Open enrollment has begun for Villanova’s newly online HR ... whose busy schedules can’t accommodate a campus-based program. With the ... in March 2010, location is no longer a barrier to ...
(Date:12/17/2009)... -- CareFusion Corporation (NYSE: CFN ) announced ... mini-tender offer by TRC Capital Corporation (TRC) to purchase ... representing approximately 1.8 percent of the shares of common ... is 4.62 percent below the share closing price of ... full trading day prior to the offer. CareFusion also ...
Breaking Medicine News(10 mins):Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2[0] Phyhealth Issues September 30, 2009 Financial Statements[0] Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work[0] Umbilical cord could be new source of plentiful stem cells, say Pitt researchers[0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital
deploynetworkpenetratevisibledesignedrewardlateralizedfMRIyetinkswhaletoleratedvirotherapyHibernation
Other Tagsabstinence 2abstinence 3abstinence 4consisting 2consisting 3consisting 4consisting 5consisting 6dizziness 2lycopene 2assisted 2assisted 3assisted 4assisted 5assisted 6calculate 2controversy 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |